Key result
SGLT2 inhibitors reduce all-cause mortality ~34% in women with HFpEF but show no effect in men.
Why the study?
Although left ventricular diastolic dysfunction is equally common in elderly men and women, HFpEF predominantly affects women, leaving the mechanisms of this sex-specific progression unclear.
This review highlights the critical need for sex-specific research to understand why women with left ventricular diastolic dysfunction are more likely to progress to HFpEF than men.
Answers are grounded in this paper and cite their sources.
Should not yet guide sex-specific SGLT2 inhibitor use in HFpEF; hypothesis-generating and requires dedicated trials.
Diastolic dysfunction of the left ventricle (LVDD) is equally common in elderly women and men. LVDD is a condition that can remain latent for a long time but is also held responsible for elevated left ventricular filling pressures and high pulmonary pressures that may result in (exercise-induced) shortness of breath. This symptom is the hallmark of heart failure with preserved ejection fraction (HFpEF) which is predominantly found in women as compared to men within the HF spectrum. Given the mechanistic role of LVDD in the development of HFpEF, we review risk factors and mechanisms that may be responsible for this sex-specific progression of LVDD towards HFpEF from an epidemiological point-of-view and propose future research directions.
No takes yet. Share an insight, caveat, or question.
Ommen et al. (2022) conducted a review in Heart failure with preserved ejection fraction (HFpEF). Sodium-glucose cotransporter 2 (SGLT2) inhibitors was evaluated on Cardiovascular mortality and heart failure hospitalization (HR 0.66, 95% CI 0.48-0.90). SGLT2 inhibitors reduced the risk of all-cause mortality in women with HFpEF (HR 0.66) while no effect was observed in men (HR 1.06).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: